Welcome to our dedicated page for Alvotech SEC filings (Ticker: ALVO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Alvotech (ALVO) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures as a foreign private issuer. Alvotech files annual reports on Form 20-F and frequent current reports on Form 6-K, which together document key developments in its biosimilar business, capital structure and regulatory interactions. These filings often incorporate press releases by reference and indicate how specific information is treated for purposes of the U.S. securities laws.
Form 6-K current reports for Alvotech commonly include business updates, earnings announcements and details on regulatory milestones. Examples from recent filings include guidance ranges for revenues and adjusted EBITDA, discussion of complete response letters (CRLs) from the U.S. Food and Drug Administration for certain biosimilar candidates, and descriptions of settlement and license agreements for products such as AVT06, a proposed biosimilar to Eylea. Other 6-Ks report on European and Japanese marketing approvals for AVT03 (denosumab), AVT05 (golimumab) and AVT06 (aflibercept), as well as EMA committee opinions and court decisions related to manufacturing activities.
Alvotech’s filings also describe financing transactions, including senior unsecured convertible bonds and other debt facilities. The company explains coupon terms, conversion conditions into Swedish Depositary Receipts, use of proceeds for its research and development pipeline, and lock-up or anti-dilution provisions. These disclosures help investors understand how Alvotech funds its biosimilar development, manufacturing scale-up and global launches.
On this page, Stock Titan surfaces Alvotech’s SEC reports as they are filed with EDGAR and can pair them with AI-powered summaries that clarify complex sections. Users can quickly see which filings contain business updates, regulatory news or capital markets activity, and can also track how non-IFRS measures such as adjusted EBITDA are defined and used in the company’s disclosures. This makes it easier to interpret lengthy documents like Form 6-K exhibits and to follow the evolution of Alvotech’s biosimilar portfolio and financial profile over time.
Alvotech filed a report describing an internal share transfer within a shareholder group closely associated with its CEO and chairman, Róbert Wessman. On January 30, 2026, ATP Holdings ehf. disposed of 2,701,617 Alvotech shares at USD 4.74 per share, while Aztiq Pharma Partners S.à r.l. acquired the same 2,701,617 shares at the same price. The company explains that ATP Holdings ehf. belongs to the Aztiq group, so the deal represents a transfer of shares within that group rather than a third‑party transaction. The report also notes that, excluding one exhibit, it is incorporated by reference into several existing Alvotech registration statements.
Alvotech reported positive top-line results from a pivotal pharmacokinetic study of AVT80, its proposed subcutaneous biosimilar to Entyvio (vedolizumab). The randomized, double-blind trial in healthy adults met all primary endpoints for pharmacokinetics, safety, tolerability and immunogenicity after a single 108 mg/0.68 mL injection.
The study is considered pivotal to demonstrate clinical similarity for both AVT80 and AVT16, Alvotech’s subcutaneous and intravenous Entyvio biosimilar candidates, and supports progressing toward regulatory submissions. Entyvio generated about US$6.4 billion in combined worldwide net revenues in 2025, highlighting the commercial potential if these biosimilars are eventually approved.
Alvotech has entered into supply and commercialization agreements with Sandoz covering multiple biosimilar candidates in Canada, Australia and New Zealand. The collaboration is designed to create commercial pathways for Alvotech’s biosimilar portfolio in these markets ahead of regulatory approvals.
In Canada, the agreement covers one ophthalmology biosimilar candidate supplied as a prefilled syringe for intravitreal injection. In Australia and New Zealand, it covers three biosimilar candidates in immunology and gastroenterology, in multiple formulations. Sandoz will handle regulatory submissions, commercialization and distribution, while Alvotech will manage development, global clinical activities and manufacturing and supply finished product under exclusive supply arrangements.
Alvotech has reached a global licensing and settlement agreement with Regeneron and Bayer, resolving all remaining patent disputes worldwide for its aflibercept biosimilar to Eylea® 2mg, already approved in the EEA, United Kingdom and Japan.
The deal grants Alvotech worldwide rights to manufacture and supply its commercial partners and sets staged launch dates: marketing and sales from January 1, 2026 in the United Kingdom and Canada, from May 1, 2026 in the European Economic Area and other non‑U.S. countries, and from November 1, 2026 in Japan for all approved indications, alongside a previously announced Q4 2026 license entry date for the U.S., pending regulatory approval.
Alvotech furnished a Form 6-K describing recent share transactions by a person closely associated with its CEO and chairman, Róbert Wessman, and how these were reported to the Luxembourg regulator. The company notes that this report, excluding Exhibits 99.1 and 99.2, is incorporated by reference into several existing shelf and employee share plan registration statements.
Alvotech states that ATP Holdings ehf. reported acquiring 4,812,257 Alvotech shares on December 17, 2025 at SEK 44.06 per share and selling 2,110,640 shares on December 19, 2025 at the same price, based on forms filed with the Luxembourg CSSF. The company explains that this corrects an earlier announcement that had mistakenly described the December 19, 2025 transaction as an acquisition. The detailed regulatory notifications are furnished as Exhibits 99.1 and 99.2, which are not deemed filed for liability purposes.
Alvotech reported share purchases in the company by entities closely associated with its leadership. On January 6, 2026, it announced that Alvogen Lux Holdings S.a. r.l., a person closely associated with senior management and board members, acquired 7,007,321 Alvotech shares on December 17, 2025 at SEK 44.06 per share. The company also announced that ATP Holdings ehf. acquired 4,812,257 Alvotech shares on December 17, 2025 at SEK 44.06 per share and a further 2,110,640 shares on December 19, 2025 at the same price. These transactions were notified to the Luxembourg financial regulator using HOS-2 forms, which are furnished as exhibits to this report.
Alvotech is implementing a planned CEO succession in which founder Róbert Wessman will leave the Chief Executive Officer role at the end of the first quarter of 2026 and continue as full-time Executive Chairman. Lisa Graver, currently a board member and long-time colleague of Wessman, has been appointed to succeed him as CEO, with a transition process beginning immediately and her stepping down from the board once she assumes the role. The company highlights that its biosimilar platform now includes a pipeline of 30 products in development and five biosimilars already approved and marketed globally, underscoring the leadership change as part of the next phase of its growth.
Alvotech provided a business update and detailed new financing. The company reaffirmed its updated 2025 outlook, expecting total revenue between $570 and $600 million and adjusted EBITDA of $130 to $150 million. For 2026, it targets total revenue of $650 to $700 million and adjusted EBITDA of $180 to $220 million. This guidance factors in potential delays and Complete Response Letters from the U.S. FDA for several biosimilar candidates, assumes possible receipt of a CRL for AVT03, and is based on an assumption that U.S. marketing approvals for pending applications are received by late 2026.
The company also noted a settlement and license agreement with Regeneron Pharmaceuticals that grants AVT06, its proposed Eylea biosimilar, a U.S. license entry date in the fourth quarter of 2026, or earlier if certain conditions are met. Separately, Alvotech completed an offshore offering of $108 million senior unsecured convertible bonds due 2030, carrying a 6.875% coupon and initially convertible into Swedish Depositary Receipts at $5.9224 per SDR, a 25% premium to a $4.7379 reference price. Net proceeds are intended to be used to invest in the R&D pipeline, scale and product launches.
Alvotech reported that its product AVT03, a biosimilar to Prolia and Xgeva (both denosumab), has been approved for marketing in the European Economic Area.
This approval means Alvotech can market AVT03 across the EEA, potentially opening a new revenue stream in the osteoporosis and oncology-related bone disease markets targeted by the reference medicines. The news was communicated through a press release dated November 24, 2025, which is furnished as an exhibit to this report.
Alvotech filed a Form 6-K to share regulatory news about one of its biosimilar products. The company announced that AVT05, a biosimilar to Simponi (golimumab), has been approved for marketing in the European Economic Area. This approval means Alvotech can commercialize AVT05 in European markets covered by the EEA, potentially expanding its biosimilar portfolio reach. The filing also notes that the accompanying press release is furnished as an exhibit but is not incorporated by reference into the company’s securities registration statements.